Alterity Therapeutics (PRNAD) Share-based Compensation (IS) (2022 - 2025)

Alterity Therapeutics (PRNAD) has reported Share-based Compensation (IS) for 4 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Share-based Compensation (IS) rose 179.85% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $2.6 million (changed N/A YoY), while the FY2024 annual figure was $581.2 billion, down 10.03% from the prior year.
• Share-based Compensation (IS) came in at $1.5 million for Q4 2025 at Alterity Therapeutics, up from $519710.4 in the prior quarter.
• The five-year high for Share-based Compensation (IS) was $1.5 million in Q4 2025, with the low at $203295.9 in Q4 2023.
• Average Share-based Compensation (IS) over 4 years is $647382.0, with a median of $465904.8 recorded in 2022.
• Across the five-year window, Share-based Compensation (IS) slumped 50.67% in 2023 and soared 179.85% in 2025, its largest moves.
• Year by year, Share-based Compensation (IS) stood at $412099.2 in 2022, then sank by 50.67% to $203295.9 in 2023, then jumped by 155.64% to $519710.4 in 2024, then jumped by 179.85% to $1.5 million in 2025.
• According to Business Quant data, Share-based Compensation (IS) over the past three periods registered $1.5 million, $519710.4, and $203295.9 for Q4 2025, Q4 2024, and Q4 2023 respectively.